ClinicalTrials.gg
CompletedNCT00549549Updated Feb 21, 2021Results posted

Celebrex In Acute Gouty Arthritis Study

A Phase 3 interventional study of Indomethacin and Celecoxib in Arthritis, Gouty, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 81 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Arthritis, Gouty with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Arthritis, Gouty · United States.

Enrollment
4th of 14
402 · median 225
Started
2008
with 3 others
Phase 3
5 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
1 of 15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 15 studies in Arthritis, Gouty with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 3, and was the 1st registered.

Arthritis, Gouty

47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.

Browse Arthritis, Gouty studies →

Open to participants now

3 of the 15 studies in Arthritis, Gouty with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arthritis, Gouty with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.

03

Conditions studied

  • Arthritis, Gouty

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria for acute arthritis of primary gout;
  • Onset of pain from an acute gouty arthritis attack within 48 hours prior to Screening/Baseline (Visit 1);
  • A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient's assessment of pain intensity in the index joint (5-point scale:0-4) at Screening/Baseline.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any other type of arthritis including those types suspected of being infectious in origin in the index joint or presence of any acute trauma of the index joint. Patients with osteoarthritis will be included as long as it is mild or moderate (according to investigator's criteria) and it does not affect the index joint;
  • Acute polyarticular gout involving greater than 4 joints or chronic gout.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
402 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Indomethacin

  • Experimental
    2

    Drug: Celecoxib

  • Experimental
    3

    Drug: Celecoxib

  • Experimental
    4

    Drug: Celecoxib

Interventions

  • indomethacin 50 mg three times a day (TID) for 8 days.

  • An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.

  • An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.

  • Celecoxib 50 mg two times a day (BID) for 8 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity

    The Patient's Pain Intensity in the Index Joint for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate (2), Severe (3), or Extreme (4).

    Time frame: Baseline and Day 2

Secondary outcomes

  1. Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness

    Tenderness was assessed on the basis of palpation or passive motion using a 4 point scale with the following ratings: the patient had no tenderness (0), the patient complained of pain (1), the patient complained of pain and winced (2) and the patient complained of pain, winced, and withdrew (3).

    Time frame: Baseline, Day 5, Day 9, and Day 14/Early Termination

  2. Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Swelling

    Swelling was assessed using a 4 point scale with the following ratings: none (0), palpable (1), visible (2), and bulging beyond joint margins (3)

    Time frame: Baseline, Days 5, 9 and 14/Early Termination

  3. Number of Participants With Redness Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14/Early Termination

    Redness was assessed by the physician as present or absent.

    Time frame: Baseline, Day 5, Day 9 and Day 14/Early Termination

  4. Number of Participants With Warmth Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14

    Warmth was assessed by the physician as present or absent.

    Time frame: Baseline, Day 5, Day 9 and Day 14

  5. Change From Baseline in Patient's Assessment of Pain Intensity

    The Patient's assessment of pain for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).

    Time frame: Baseline, Day 2 to Day 13

  6. Change From Baseline in Patient's Assessment of Pain Intensity on Day 1

    The patient's assessment of pain was assessed by completion of the following 5 point scale: my pain at this time is none (0), mild (1), moderate, (2), severe (3), and extreme (4).

    Time frame: Baseline, 2, 4, 8, 12 hours postdose Day 1, Day 2 (24 hours and 32 hours post first dose)

  7. Change From Baseline in Time Weighted Average of Patient's Assessment of Pain Intensity Over 8, 12, and 24 Hours

    Time weighted average over 8 (TWA-8), 12 (TWA-12) and 24 (TWA-24) hours post first dose of study medication on Day 1. Positive TWA values represent a reduction in pain intensity

    Time frame: Baseline, 8, 12, and 24 hours post first dose

  8. Number of Participants With ≥30% and ≥50% Reduction From Baseline to Day 2 in Patient's Assessment of Pain Intensity

    The Patient's assessment of pain was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).

    Time frame: Baseline, Day 2

  9. Participant's Assessment of Pain Intensity for the Average Pain Intensity at Baseline

    The participant's assessment of pain was assessed by completion of the following 5 point scale: My pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).

    Time frame: Baseline

  10. Percentage Change From Baseline in the Patient's Assessment of Pain Intensity for the Average Pain Intensity on Days 2-4, Days 2-8 and Days 2-13

    The participant's assessment of pain was assessed by completion of the following 5 point scale: My change in pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4). Average change over days was calculated by taking the change from Baseline to the average Pain Intensity score over the days for each patient.

    Time frame: Baseline to Day 13

  11. Number of Participants With Withdrawal From Treatment Due to Lack of Efficacy

    Withdrawal due to lack of efficacy was assessed from Days 1 to 8

    Time frame: Day 1 to Day 8

  12. Participants Global Evaluation of Study Medication Score

    The participant rated the study medication that they received during the study by completing the following question: How would you rate the study medication you received for pain? 4=Excellent, 3=Good, 2=Fair, 1=Poor

    Time frame: Day 9

  13. Number of Participants With Pre-specified Gastrointestinal (GI) Adverse Events

    The gastrointestinal tolerability was measured by incidence of moderate or severe GI adverse events (nausea, abdominal pain and dyspepsia)

    Time frame: Baseline to Day 14/Early Termination

  14. Number of Participants With Moderate or Severe Central Nervous System (CNS) Adverse Events

    The pre-specfied CNS AEs were headache, nausea, dizziness, vertigo, vomiting and somnolence.

    Time frame: Baseline to Day 14/Early Termination

07

Results

Posted Feb 24, 2011
Limitations and caveats
Patients Global Evaluation of study medication data was collected at Day 9 only.

Participant flow

Participant flow — Overall Study
MilestoneCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Started1019999103
Treated1019998102
Completed77778278
Not completed24221725
Withdrew: Adverse event5319
Withdrew: Lack of efficacy9642
Withdrew: Lost to follow-up1012
Withdrew: Withdrawal by subject0410
Withdrew: Other99911
Withdrew: Randomized but not treated0011

Outcome measures

PrimaryChange From Baseline to Day 2 in Patient's Assessment of Pain Intensity

The Patient's Pain Intensity in the Index Joint for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate (2), Severe (3), or Extreme (4).

Time frame:
Baseline and Day 2
Reported as:
Mean · Scores on a scale
Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline3.03 ± 0.672.73 ± 0.622.84 ± 0.692.83 ± 0.76
Change at Day 2-1.14 ± 1.10-1.23 ± 0.97-1.51 ± 1.11-1.62 ± 0.97
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Median difference (final values): -0.46 · 95% CI -0.74 to -0.18
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Median difference (final values): -0.24 · 95% CI -0.52 to 0.04
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.57 · 95% CI 0.29 to 0.84
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.33 · 95% CI 0.05 to 0.60
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.11 · 95% CI -0.17 to 0.39
SecondaryChange From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness

Tenderness was assessed on the basis of palpation or passive motion using a 4 point scale with the following ratings: the patient had no tenderness (0), the patient complained of pain (1), the patient complained of pain and winced (2) and the patient complained of pain, winced, and withdrew (3).

Time frame:
Baseline, Day 5, Day 9, and Day 14/Early Termination
Reported as:
Mean · Scores on a scale
Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline2.39 ± 0.722.15 ± 0.752.26 ± 0.652.13 ± 0.70
Change at Day 5-1.44 ± 0.96-1.39 ± 0.89-1.58 ± 0.93-1.52 ± 0.86
Change at Day 9-1.75 ± 0.98-1.64 ± 0.93-1.84 ± 0.92-1.65 ± 0.87
Change at Day 14/Early Termination-1.74 ± 1.09-1.66 ± 1.01-1.94 ± 0.88-1.64 ± 0.93
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.08 · 95% CI -0.29 to 0.14
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.20 · 95% CI -0.42 to 0.02
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.26 · 95% CI 0.04 to 0.47
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.18 · 95% CI -0.04 to 0.39
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.06 · 95% CI -0.16 to 0.27
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.05 · 95% CI -0.26 to 0.16
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.19 · 95% CI -0.40 to 0.03
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.10 · 95% CI -0.11 to 0.32
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.05 · 95% CI -0.16 to 0.27
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.08 · 95% CI -0.30 to 0.13
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.12 · 95% CI -0.33 to 0.10
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.32 · 95% CI -0.53 to -0.11
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.16 · 95% CI -0.05 to 0.37
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.04 · 95% CI -0.17 to 0.25
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.16 · 95% CI -0.38 to 0.05
SecondaryChange From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Swelling

Swelling was assessed using a 4 point scale with the following ratings: none (0), palpable (1), visible (2), and bulging beyond joint margins (3)

Time frame:
Baseline, Days 5, 9 and 14/Early Termination
Reported as:
Mean · Scores on a scale
Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Swelling
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline2.16 ± 0.732.08 ± 0.652.09 ± 0.652.01 ± 0.75
Change at Day 5-1.22 ± 1.09-1.21 ± 1.05-1.27 ± 0.97-1.20 ± 0.96
Change at Day 9-1.47 ± 1.18-1.54 ± 1.00-1.62 ± 0.95-1.58 ± 0.94
Change at Day 14/Early Termination-1.55 ± 1.18-1.63 ± 0.98-1.78 ± 0.97-1.58 ± 0.94
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.04 · 95% CI -0.29 to 0.22
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.09 · 95% CI -0.35 to 0.16
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.08 · 95% CI -0.17 to 0.34
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.05 · 95% CI -0.20 to 0.30
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.01 · 95% CI -0.26 to 0.25
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.12 · 95% CI -0.36 to 0.11
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.20 · 95% CI -0.44 to 0.04
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.22 · 95% CI -0.01 to 0.46
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.10 · 95% CI -0.14 to 0.33
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.02 · 95% CI -0.22 to 0.26
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.14 · 95% CI -0.38 to 0.10
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.28 · 95% CI -0.52 to -0.04
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.16 · 95% CI -0.08 to 0.39
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.02 · 95% CI -0.22 to 0.26
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.12 · 95% CI -0.36 to 0.12
SecondaryNumber of Participants With Redness Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14/Early Termination

Redness was assessed by the physician as present or absent.

Time frame:
Baseline, Day 5, Day 9 and Day 14/Early Termination
Reported as:
Number · Participants
Number of Participants With Redness Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14/Early Termination
ParticipantsCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline84887985
Day 527292623
Day 912151311
Day 14/Early termination1515713
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.6402
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.9739
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.4581
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.2962
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.4951
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.4957
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.8364
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.6892
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.4110
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.5981
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.9317
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.0831
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.5747
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.6204
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.2556
SecondaryNumber of Participants With Warmth Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14

Warmth was assessed by the physician as present or absent.

Time frame:
Baseline, Day 5, Day 9 and Day 14
Reported as:
Number · Participants
Number of Participants With Warmth Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14
ParticipantsCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline89919188
Day 525162221
Day 9138911
DAY 14/E_TERM1971115
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.1444
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.7532
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.4722
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.3878
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.6717
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.3098
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.4356
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.5703
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.4986
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.7855
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.0169
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.1353
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.3690
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.0787
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.5687
SecondaryChange From Baseline in Patient's Assessment of Pain Intensity

The Patient's assessment of pain for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).

Time frame:
Baseline, Day 2 to Day 13
Reported as:
Mean · Scores on a scale
Change From Baseline in Patient's Assessment of Pain Intensity
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline3.03 ± 0.672.73 ± 0.622.84 ± 0.692.83 ± 0.76
Change at Day 1-0.65 ± 0.87-0.85 ± 0.86-1.06 ± 1.08-1.10 ± 0.92
Change at Day 2-1.14 ± 1.10-1.23 ± 0.97-1.51 ± 1.11-1.62 ± 0.97
Change at Day 3-1.32 ± 1.15-1.42 ± 0.98-1.78 ± 1.09-1.84 ± 0.97
Change at Day 4-1.52 ± 1.16-1.60 ± 0.98-1.96 ± 1.08-2.02 ± 1.00
Change at Day 5-1.52 ± 1.16-1.67 ± 1.04-2.05 ± 1.10-2.04 ± 1.03
Change at Day 6-1.68 ± 1.15-1.84 ± 1.05-2.12 ± 1.06-2.11 ± 1.01
Change at Day 7-1.79 ± 1.23-1.90 ± 1.16-2.29 ± 1.05-2.15 ± 1.02
Change at Day 8-1.88 ± 1.26-1.95 ± 1.12-2.30 ± 0.98-2.16 ± 1.04
Change at Day 9-1.86 ± 1.27-1.96 ± 1.12-2.24 ± 1.04-2.19 ± 1.08
Change at Day 10-1.90 ± 1.27-1.99 ± 1.13-2.23 ± 1.13-2.17 ± 1.01
Change at Day 11-1.89 ± 1.31-1.94 ± 1.13-2.22 ± 1.15-2.15 ± 1.02
Change at Day 12-1.93 ± 1.32-1.95 ± 1.18-2.27 ± 1.09-2.07 ± 1.07
Change at Day 13/Early termination-1.91 ± 1.34-1.95 ± 1.18-2.27 ± 1.08-1.98 ± 1.11
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.35 · 95% CI -0.60 to -0.10
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.50 · 95% CI -0.75 to -0.25
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.54 · 95% CI 0.29 to 0.78
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.19 · 95% CI -0.06 to 0.44
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.03 · 95% CI -0.21 to 0.28
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.24 · 95% CI -0.52 to 0.04
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.46 · 95% CI -0.74 to -0.18
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.57 · 95% CI 0.29 to 0.84
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.33 · 95% CI 0.05 to 0.60
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.11 · 95% CI -0.17 to 0.39
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.25 · 95% CI -0.53 to 0.03
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.55 · 95% CI -0.83 to -0.26
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.60 · 95% CI 0.32 to 0.88
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.36 · 95% CI 0.08 to 0.64
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.06 · 95% CI -0.22 to 0.34
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.28 · 95% CI -0.56 to -0.00
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.56 · 95% CI -0.84 to -0.28
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.62 · 95% CI 0.35 to 0.90
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.34 · 95% CI 0.07 to 0.62
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.07 · 95% CI -0.21 to 0.34
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.35 · 95% CI -0.64 to -0.07
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.66 · 95% CI -0.94 to -0.38
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.65 · 95% CI 0.37 to 0.93
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.29 · 95% CI 0.02 to 0.57
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.01 · 95% CI -0.29 to 0.27
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.37 · 95% CI -0.65 to -0.10
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.57 · 95% CI -0.84 to -0.29
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.56 · 95% CI 0.29 to 0.83
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.19 · 95% CI -0.08 to 0.46
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.01 · 95% CI -0.28 to 0.26
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.32 · 95% CI -0.61 to -0.04
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.63 · 95% CI -0.92 to -0.34
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.49 · 95% CI 0.21 to 0.78
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.17 · 95% CI -0.11 to 0.45
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.14 · 95% CI -0.42 to 0.15
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.29 · 95% CI -0.57 to -0.00
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.55 · 95% CI -0.84 to -0.27
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.42 · 95% CI 0.14 to 0.70
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.13 · 95% CI -0.15 to 0.41
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.14 · 95% CI -0.42 to 0.14
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.32 · 95% CI -0.61 to -0.02
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.53 · 95% CI -0.82 to -0.23
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.47 · 95% CI 0.18 to 0.76
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.16 · 95% CI -0.13 to 0.44
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.06 · 95% CI -0.35 to 0.23
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.29 · 95% CI -0.59 to 0.01
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.46 · 95% CI -0.76 to -0.16
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.40 · 95% CI 0.10 to 0.69
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.11 · 95% CI -0.18 to 0.41
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.07 · 95% CI -0.36 to 0.23
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.26 · 95% CI -0.56 to 0.05
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.47 · 95% CI -0.77 to -0.17
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.40 · 95% CI 0.10 to 0.69
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.14 · 95% CI -0.16 to 0.44
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.07 · 95% CI -0.37 to 0.23
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.22 · 95% CI -0.53 to 0.09
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.46 · 95% CI -0.77 to -0.15
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.27 · 95% CI -0.04 to 0.57
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.05 · 95% CI -0.25 to 0.36
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.19 · 95% CI -0.50 to 0.11
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.24 · 95% CI -0.56 to 0.07
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.50 · 95% CI -0.81 to -0.19
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.20 · 95% CI -0.10 to 0.51
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.04 · 95% CI -0.35 to 0.26
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.30 · 95% CI -0.60 to 0.01
SecondaryChange From Baseline in Patient's Assessment of Pain Intensity on Day 1

The patient's assessment of pain was assessed by completion of the following 5 point scale: my pain at this time is none (0), mild (1), moderate, (2), severe (3), and extreme (4).

Time frame:
Baseline, 2, 4, 8, 12 hours postdose Day 1, Day 2 (24 hours and 32 hours post first dose)
Reported as:
Mean · Scores on a scale
Change From Baseline in Patient's Assessment of Pain Intensity on Day 1
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline3.03 ± 0.672.73 ± 0.622.84 ± 0.692.83 ± 0.76
Change at Day 1, 2 HR-0.32 ± 0.75-0.28 ± 0.67-0.45 ± 0.77-0.57 ± 0.88
Change at Day 1, 4 HR-0.53 ± 0.82-0.54 ± 0.69-0.70 ± 0.90-0.81 ± 0.92
Change at Day 1, 8 HR-0.64 ± 0.92-0.58 ± 0.73-0.87 ± 1.05-0.98 ± 0.94
Change at Day 1, 12 HR-0.73 ± 1.02-0.75 ± 0.79-1.02 ± 1.11-1.09 ± 0.96
Change at Day 2, 0 HR-0.93 ± 1.00-0.98 ± 0.88-1.15 ± 1.14-1.26 ± 0.93
Change at Day 2, 8 HR-1.08 ± 1.07-1.07 ± 0.96-1.31 ± 1.03-1.46 ± 0.93
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.07 · 95% CI -0.28 to 0.14
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.18 · 95% CI -0.39 to 0.03
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.31 · 95% CI 0.11 to 0.52
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.24 · 95% CI 0.04 to 0.45
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.13 · 95% CI -0.08 to 0.34
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.14 · 95% CI -0.37 to 0.08
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.25 · 95% CI -0.48 to -0.03
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.36 · 95% CI 0.14 to 0.58
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.22 · 95% CI 0.00 to 0.44
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.11 · 95% CI -0.11 to 0.34
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.07 · 95% CI -0.32 to 0.17
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.31 · 95% CI -0.56 to -0.06
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.42 · 95% CI 0.18 to 0.67
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.35 · 95% CI 0.11 to 0.59
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.11 · 95% CI -0.13 to 0.36
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.16 · 95% CI -0.42 to 0.10
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.37 · 95% CI -0.63 to -0.11
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.45 · 95% CI 0.19 to 0.70
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.29 · 95% CI 0.03 to 0.55
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.08 · 95% CI -0.18 to 0.34
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.19 · 95% CI -0.46 to 0.07
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.31 · 95% CI -0.57 to -0.04
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.42 · 95% CI 0.16 to 0.68
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.23 · 95% CI -0.04 to 0.49
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.11 · 95% CI -0.15 to 0.38
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): -0.13 · 95% CI -0.40 to 0.14
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): -0.32 · 95% CI -0.59 to -0.05
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.47 · 95% CI 0.20 to 0.74
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.34 · 95% CI 0.08 to 0.61
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): 0.15 · 95% CI -0.11 to 0.42
SecondaryChange From Baseline in Time Weighted Average of Patient's Assessment of Pain Intensity Over 8, 12, and 24 Hours

Time weighted average over 8 (TWA-8), 12 (TWA-12) and 24 (TWA-24) hours post first dose of study medication on Day 1. Positive TWA values represent a reduction in pain intensity

Time frame:
Baseline, 8, 12, and 24 hours post first dose
Reported as:
Mean · Scores on a scale
Change From Baseline in Time Weighted Average of Patient's Assessment of Pain Intensity Over 8, 12, and 24 Hours
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Baseline3.03 ± 0.672.73 ± 0.622.84 ± 0.692.83 ± 0.76
Change at 8 HR0.44 ± 0.660.42 ± 0.550.59 ± 0.740.69 ± 0.75
Change at 12 HR0.52 ± 0.730.50 ± 0.580.71 ± 0.820.81 ± 0.79
Change at 24 HR0.67 ± 0.810.68 ± 0.660.89 ± 0.930.99 ± 0.82
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Median difference (final values): 0.09 · 95% CI -0.09 to 0.27
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): 0.22 · 95% CI 0.04 to 0.40
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.32 · 95% CI -0.50 to -0.14
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.23 · 95% CI -0.41 to -0.05
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.10 · 95% CI -0.28 to 0.08
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): 0.10 · 95% CI -0.10 to 0.29
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): 0.26 · 95% CI 0.06 to 0.45
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.36 · 95% CI -0.55 to -0.16
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.26 · 95% CI -0.45 to -0.07
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.10 · 95% CI -0.29 to 0.09
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): 0.14 · 95% CI -0.08 to 0.35
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): 0.29 · 95% CI 0.08 to 0.51
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.40 · 95% CI -0.61 to -0.18
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.26 · 95% CI -0.47 to -0.05
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.10 · 95% CI -0.32 to 0.11
SecondaryNumber of Participants With ≥30% and ≥50% Reduction From Baseline to Day 2 in Patient's Assessment of Pain Intensity

The Patient's assessment of pain was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).

Time frame:
Baseline, Day 2
Reported as:
Number · Participants
Number of Participants With ≥30% and ≥50% Reduction From Baseline to Day 2 in Patient's Assessment of Pain Intensity
ParticipantsCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Reduction in Pain Intensity >= 30%58697582
Reduction in Pain Intensity >= 50%43576371
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.0459
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.0017
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.0001
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.0410
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.5592
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.0277
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.0018
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = <.0001
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.0394
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.4603
SecondaryParticipant's Assessment of Pain Intensity for the Average Pain Intensity at Baseline

The participant's assessment of pain was assessed by completion of the following 5 point scale: My pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).

Time frame:
Baseline
Reported as:
Mean · Units on a scale
Participant's Assessment of Pain Intensity for the Average Pain Intensity at Baseline
Units on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Participant's Assessment of Pain Intensity for the Average Pain Intensity at Baseline3.03 ± 0.672.73 ± 0.622.84 ± 0.692.83 ± 0.76
SecondaryPercentage Change From Baseline in the Patient's Assessment of Pain Intensity for the Average Pain Intensity on Days 2-4, Days 2-8 and Days 2-13

The participant's assessment of pain was assessed by completion of the following 5 point scale: My change in pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4). Average change over days was calculated by taking the change from Baseline to the average Pain Intensity score over the days for each patient.

Time frame:
Baseline to Day 13
Reported as:
Mean · Percentage change
Percentage Change From Baseline in the Patient's Assessment of Pain Intensity for the Average Pain Intensity on Days 2-4, Days 2-8 and Days 2-13
Percentage changeCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Average change over days 2 - 4-44.13 ± 36.66-53.15 ± 34.17-60.11 ± 33.572.83 ± 0.76
Average change over days 2 - 8-51.36 ± 35.57-61.83 ± 34.68-69.41 ± 30.86-70.05 ± 27.45
Average change over days 2 - 13-56.11 ± 36.47-66.26 ± 35.55-73.59 ± 29.74-72.35 ± 27.39
SecondaryNumber of Participants With Withdrawal From Treatment Due to Lack of Efficacy

Withdrawal due to lack of efficacy was assessed from Days 1 to 8

Time frame:
Day 1 to Day 8
Reported as:
Number · Participants
Number of Participants With Withdrawal From Treatment Due to Lack of Efficacy
ParticipantsCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Day 12100
Any time during treatment10843
Any time during study11954
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.5528
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.1779
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.1754
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.3384
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.5005
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.0845
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.0213
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.1231
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.6636
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.5378
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · Cochran-Mantel-Haenszel · p = 0.0818
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.0317
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.1592
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.7956
SecondaryParticipants Global Evaluation of Study Medication Score

The participant rated the study medication that they received during the study by completing the following question: How would you rate the study medication you received for pain? 4=Excellent, 3=Good, 2=Fair, 1=Poor

Time frame:
Day 9
Reported as:
Mean · Scores on a scale
Participants Global Evaluation of Study Medication Score
Scores on a scaleCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Participants Global Evaluation of Study Medication Score3.04 ± 0.873.11 ± 0.853.27 ± 0.693.33 ± 0.75
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · ANCOVA · Mean difference (final values): 0.07 · 95% CI -0.17 to 0.31
  • Celecoxib 50 mg vs Celecoxib 800/400 mg · ANCOVA · Mean difference (final values): 0.22 · 95% CI -0.02 to 0.46
  • Celecoxib 50 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.26 · 95% CI -0.50 to -0.02
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.19 · 95% CI -0.43 to 0.05
  • Celecoxib 800/400 mg vs Indomethacin 50 mg · ANCOVA · Mean difference (final values): -0.04 · 95% CI -0.28 to 0.19
SecondaryNumber of Participants With Pre-specified Gastrointestinal (GI) Adverse Events

The gastrointestinal tolerability was measured by incidence of moderate or severe GI adverse events (nausea, abdominal pain and dyspepsia)

Time frame:
Baseline to Day 14/Early Termination
Reported as:
Number · Participants
Number of Participants With Pre-specified Gastrointestinal (GI) Adverse Events
ParticipantsCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Number of Participants With Pre-specified Gastrointestinal (GI) Adverse Events1023
Statistical analysis
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.3173
SecondaryNumber of Participants With Moderate or Severe Central Nervous System (CNS) Adverse Events

The pre-specfied CNS AEs were headache, nausea, dizziness, vertigo, vomiting and somnolence.

Time frame:
Baseline to Day 14/Early Termination
Reported as:
Number · Participants
Number of Participants With Moderate or Severe Central Nervous System (CNS) Adverse Events
ParticipantsCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Number of Participants With Moderate or Severe Central Nervous System (CNS) Adverse Events3215
Statistical analysis
  • Celecoxib 50 mg vs Celecoxib 400/200 mg · Cochran-Mantel-Haenszel · p = 0.4724
  • Celecoxib 50 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.7316
  • Celecoxib 400/200 mg vs Indomethacin 50 mg · Cochran-Mantel-Haenszel · p = 0.7316

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib 50 mg—0/101 (0%)22/101 (21.8%)
Celecoxib 400/200 mg—0/99 (0%)22/99 (22.2%)
Celecoxib 800/400 mg—0/98 (0%)21/98 (21.4%)
Indomethacin 50 mg—1/102 (1%)32/102 (31.4%)
Most frequent serious events
Most frequent serious events
EventCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Facial bones fractureInjury, poisoning and procedural complications0/1010/990/981/102
Most frequent other events
Showing 10 of 18
Most frequent other events
EventCelecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mg
Gouty arthritisMusculoskeletal and connective tissue disorders4/1017/993/986/102
GoutMetabolism and nutrition disorders2/1012/996/983/102
DizzinessNervous system disorders2/1011/992/986/102
HeadacheNervous system disorders5/1014/993/984/102
Abdominal pain upperGastrointestinal disorders1/1010/991/985/102
DiarrhoeaGastrointestinal disorders3/1012/992/985/102
ArthralgiaMusculoskeletal and connective tissue disorders1/1014/993/982/102
PyrexiaGeneral disorders4/1011/990/980/102
Pain in extremityMusculoskeletal and connective tissue disorders0/1011/993/981/102
DyspepsiaGastrointestinal disorders2/1010/992/983/102

Baseline characteristics

Age, Customized
Age, Customized(Participants)Celecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mgTotal
Between 18 and 65 years84838688341
>=65 years1716121459
Sex: Female, Male
Sex: Female, Male(Participants)Celecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mgTotal
Female1098734
Male91909095366
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Celecoxib 50 mgCelecoxib 400/200 mgCelecoxib 800/400 mgIndomethacin 50 mgTotal
White53645455226
Black11310933
Asian2218191978
Other1514151963
08

Study locations

81 sites
  • Pfizer Investigational Site
    Glendale, Arizona 85304, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85202, United States
  • Pfizer Investigational Site
    Paradise Valley, Arizona 85253, United States
  • Pfizer Investigational Site
    Peoria, Arizona 85381, United States
  • Pfizer Investigational Site
    Roseville, California 95661, United States
  • Pfizer Investigational Site
    San Diego, California 92103-6204, United States
  • Pfizer Investigational Site
    San Luis Obispo, California 93405, United States
  • Pfizer Investigational Site
    Longmont, Colorado 80501, United States
  • Pfizer Investigational Site
    Northglenn, Colorado 80234, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32607, United States
  • Pfizer Investigational Site
    Tampa, Florida 33606, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Dunwoody, Georgia 30338, United States
  • Pfizer Investigational Site
    Rockford, Illinois 61107, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40504, United States
  • Pfizer Investigational Site
    Mount Sterling, Kentucky 40353, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71105-5634, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71106, United States
  • Pfizer Investigational Site
    Wheaton, Maryland 20902, United States
  • Pfizer Investigational Site
    Lansing, Michigan 48910-8595, United States
  • Pfizer Investigational Site
    Chaska, Minnesota 55318, United States
  • Pfizer Investigational Site
    Columbia, Missouri 65203, United States
  • Pfizer Investigational Site
    Columbus, Missouri 65212, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68134, United States
  • Pfizer Investigational Site
    Mineola, New York 11501, United States
  • Pfizer Investigational Site
    Statesville, North Carolina 28625, United States
  • Pfizer Investigational Site
    Lyndhurst, Ohio 44124, United States
  • Pfizer Investigational Site
    Willoughby Hills, Ohio 44094, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Havertown, Pennsylvania 19083, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    New Tazewell, Tennessee 37825, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77701, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77706, United States
  • Pfizer Investigational Site
    Bryan, Texas 77802, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78217, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78224, United States
  • Pfizer Investigational Site
    Tyler, Texas 75701, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53295, United States
  • Pfizer Investigational Site
    Langley, British Columbia V3A 4H9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R2V 4W3, Canada
  • Pfizer Investigational Site
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Pfizer Investigational Site
    Corunna, Ontario N0N 1G0, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M3M 3E5, Canada
  • Pfizer Investigational Site
    Windsor, Ontario N8X 5A6, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 7H9, Canada
  • Pfizer Investigational Site
    Quebec, G1W 4R4, Canada
  • Pfizer Investigational Site
    Barranquilla, Atlantico 0000, Colombia
  • Pfizer Investigational Site
    Barranquilla, Atlantico 0, Colombia
  • Pfizer Investigational Site
    Bucaramanga, Santander, Colombia
  • Pfizer Investigational Site
    Cartago, Costa Rica
  • Pfizer Investigational Site
    Heredia, Costa Rica
  • Pfizer Investigational Site
    Suwon-si, Kyeongki-do 443-721, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 705-718, Korea, Republic of
  • Pfizer Investigational Site
    Mexico, D.f. 06726, Mexico
  • Pfizer Investigational Site
    Mexico, DF 06700, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44100, Mexico
  • Pfizer Investigational Site
    Lima, 11, Peru
  • Pfizer Investigational Site
    Lima, 34, Peru
  • Pfizer Investigational Site
    Lima, L27, Peru
  • Pfizer Investigational Site
    Lipa City, Batangas 4217, Philippines
  • Pfizer Investigational Site
    Las Piñas City, 1742, Philippines
  • Pfizer Investigational Site
    Manila, 1000, Philippines
  • Pfizer Investigational Site
    Manila, 1003, Philippines
  • Pfizer Investigational Site
    Manila, 1008, Philippines
  • Pfizer Investigational Site
    Quezon City, 1102, Philippines
  • Pfizer Investigational Site
    Moscow, 115522, Russian Federation
  • Pfizer Investigational Site
    Petrozavodsk, 185019, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 193015, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 194291, Russian Federation
  • Pfizer Investigational Site
    Sevilla, 41014, Spain
  • Pfizer Investigational Site
    Hualien, 970, Taiwan
  • Pfizer Investigational Site
    Taichung, 404, Taiwan
  • Pfizer Investigational Site
    Taipei, 106, Taiwan
  • Pfizer Investigational Site
    Phayathai, Bangkok 10400, Thailand
  • Pfizer Investigational Site
    Khon Kaen, 40002, Thailand
09

References and documents

Publications

  • Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17. PubMed 21849262 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2007
First posted
Oct 26, 2007
Start
Feb 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Feb 24, 2011
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00549549
Responsible party
Sponsor
First posted
Oct 26, 2007
Start date
Feb 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Feb 24, 2011
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion